Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Withdrawal Clear all
Completed Phase 1Phase 2 Interventional Results available

Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

NCT01137890
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Zonisamide, Placebo, Cocaine Hydrochloride, Neurocognitive and Performance Battery, Smoking Assessments
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Oral and IV Baclofen in Adult Volunteers

NCT01749319
View directory record Official record
Conditions
Baclofen Withdrawal Syndrome
Interventions
Oral baclofen, Intervenous baclofen
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 1 Interventional

Pilot Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients

NCT01558934
View directory record Official record
Conditions
Opioid Dependence, Methadone Withdrawal Syndrome
Interventions
Lofexidine HCl
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jul 20, 2026, 7:14 PM EDT
Not listed Phase 4 Interventional

Assessment of Valproate on Ethanol Withdrawal

NCT03235531
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Withdrawal Syndrome, Trauma, Heavy Drinking, Alcohol Use Disorder
Interventions
Valproate, Lorazepam
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 3 Interventional

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

NCT01114308
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant), placebo implant, Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Los Angeles, California • National City, California • Oceanside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

Open-Label, Safety Study of Lofexidine

NCT02363998
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Lofexidine
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
18
States / cities
Little Rock, Arkansas • Springdale, Arkansas • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal

NCT01863186
View directory record Official record
Conditions
Opioid Dependence, Acute Opioid Withdrawal Syndrome
Interventions
Lofexidine HCl, Placebo, Open Label Lofexidine HCL
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Clovis, California • Escondido, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jul 20, 2026, 7:14 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Jul 20, 2026, 7:14 PM EDT
Not listed Phase 2 Interventional

Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder

NCT04850664
View directory record Official record
Conditions
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms, Craving, Negative Affectivity
Interventions
CBOT + TAU, Sham + TAU
Drug
Lead sponsor
Evon Medics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Jul 20, 2026, 7:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Liver Transplantation With Tregs at UCSF

NCT03654040
View directory record Official record
Conditions
Liver Transplant
Interventions
arTreg, leukapheresis, cyclophosphamide, mesna, everolimus
Biological · Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Jul 20, 2026, 7:14 PM EDT
Terminated Phase 3 Interventional Results available

Preventing Alcohol Withdrawal Syndrome With Oral Baclofen

NCT02052440
View directory record Official record
Conditions
Alcohol Withdrawal Syndrome
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
21 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

NCT03891862
View directory record Official record
Conditions
Tardive Dyskinesia (TD)
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
42
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal

NCT04731935
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal
Interventions
Sparrow Therapy System
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

NCT03888066
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer, Placebos
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
133
States / cities
Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

A Study of ABT-652 in Combination With a Nonsteroidal Anti-Inflammatory Drug (NSAID) in Adults With Osteoarthritis Pain of the Knee

NCT01444365
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
ABT-652 NSAID, Placebo NSAID
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
40 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

Nicotine Patch for Marijuana Withdrawal

NCT01400243
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Nicotine, Placebo Patch
Drug
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 50 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 4 Interventional

The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients

NCT00275535
View directory record Official record
Conditions
Kidney Diseases
Interventions
Anti-thymocyte globulin, Mycophenolate mofetil, Prednisone, Tacrolimus, Sirolimus
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 3 Interventional

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1

NCT00032955
View directory record Official record
Conditions
Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
15 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
6
States / cities
Rancho Mirage, California • Orlando, Florida • Pinellas Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal

NCT00896012
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus
Procedure · Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers

NCT00900900
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
dehydroepiandrosterone (DHEA), pregnenolone, Placebo
Dietary Supplement · Drug
Lead sponsor
Jed E. Rose
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Jul 20, 2026, 7:14 PM EDT
Completed No phase listed Observational

AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)

NCT04422808
View directory record Official record
Conditions
Withdrawal Syndrome, Iatrogenic Disease
Interventions
Not listed
Lead sponsor
Wilkes University
Other
Eligibility
18 Years and older
Enrollment
2,437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome

NCT04298853
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal, Neonatal Opioid Withdrawal Syndrome
Interventions
Morphine PRN, Morphine scheduled
Drug
Lead sponsor
Indiana University
Other
Eligibility
Up to 28 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jul 20, 2026, 7:14 PM EDT
Completed Phase 1Phase 2 Interventional

The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program

NCT02431728
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
Melatonin, Matched Placebo
Dietary Supplement
Lead sponsor
Duquesne University
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Jul 20, 2026, 7:14 PM EDT